Aptevo Therapeutics Inc (APVO) is a leading biotechnology company specialized in the field of oncology and hematology. The company is committed to transforming patient’s lives by developing innovative and novel therapeutics to improve the management and treatment of serious diseases. With its headquarters in Seattle, Washington, APVO's core principle revolves around leveraging breakthroughs in medical science to address the unmet medical needs across the globe.
The company possesses an amazing track record in the domain of drug discovery and development. The advanced proprietary ADAPTIR™ (modular protein technology) platform is one of the critical pillars of their discovery efforts. This technology is designed to expand the diversity of single-chain molecules enabling the development of new drugs with enhanced therapeutic potency and improved drug-like qualities.
Aptevo Therapeutics has an impressive pipeline of products, with leading programs focused on the treatment of Cancer and Hematology. One of the company’s major marketed products is IXINITY®, which is used for the prevention, control and treatment of bleeding episodes occurring in patients with Hemophilia B.
The company operates using a strategic model of balancing short-term revenue generation through partnerships while also investing in its long-term growth through proprietary R&D. This unique business model enables APVO to retain its competitive edge and contribute significantly towards medical innovation.
Alongside its business operations, the company is also known for supporting societal initiatives by committing to environmental, social and corporate governance aspects. Aptevo Therapeutics is focused not only on creating medical breakthroughs but also on building a better world in a responsible and sustainable manner.
Aptevo Therapeutics Inc’s remarkable values are reflected by their skilled and dedicated workforce. Managed by a team of experienced professionals and guided by renowned scientific and clinical advisors, the company thrives to be at the forefront of utilizing cutting-edge technology for developing revolutionary treatments. It represents an important player in the emerging landscape of biotechnology and a promising enterprise working for the greater good of humanity.
In the dynamic environment of biotech, companies like Aptevo Therapeutics are making important contributions to the development of next-generation therapeutics which could potentially revolutionize patient care and significantly improve the quality of life for patients around the world.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Aptevo Therapeutics (NASDAQ:APVO) saw its shares drop 6.35% in pre-market trading on October 27, 2026, despite recent strong clinical data for its lead candidate mipletamig in acute myeloid leukemia, which showed a 93% clinical benefit rate. The decline is attributed to thin liquidity and dilution from a recent August financing that raised $4.5 million gross. Investors are weighing the promising, albeit early-stage, clinical data against the company's small cash reserves and the potential for further dilution.
Aptevo Therapeutics Inc. announced that ten newly diagnosed acute myeloid leukemia (AML) patients successfully progressed to allogeneic stem cell transplant after receiving a combination therapy involving mipletamig, venetoclax, and azacitidine. This clinical update was submitted in an 8-K current report, detailing the advancement of these patients toward a critical next stage of treatment. The company trades on NASDAQ under the ticker APVO, and the report was authorized by Daphne Taylor, Senior Vice President and CFO.